Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01527487 · ClinicalTrials.gov registry record · Phase 2
Trial of Eribulin/Cyclophosphamide or Docetaxel/Cyclophosphamide as Neoadjuvant Therapy in Locally Advanced HER2-Negative Breast Cancer
A Phase 2 study, sponsored by SCRI Development Innovations.
- Completed
- Registry status
- Phase 2
- Development phase
- 76
- Enrollment target
NCT01527487 is a Phase 2 study that has completed, run by SCRI Development Innovations. The registered enrollment target is 76 participants.
The verdict
NCT01527487, a Phase 2 study, has completed, sponsored by SCRI Development Innovations.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 76 participants
- Enrollment target
Study Summary
The investigators propose a randomized phase II study evaluating the pCR and toxicity profiles of combination eribulin/cyclophosphamide (ErC) and docetaxel /cyclophosphamide (TC) as neoadjuvant therapy for locally advanced HER2-negative breast cancer.
Interventions
- DRUG Cyclophosphamide
- DRUG Docetaxel
- DRUG Eribulin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 76 participants |
| Start Date | 2012-06 |
| Est. Completion | 2016-07 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01527487
The ClinicalTrials.gov registry entry for NCT01527487 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 76 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is SCRI Development Innovations, which has 146 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Cyclophosphamide is the first listed.
NCT01527487 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01527487 about?
NCT01527487 is a clinical study titled "Trial of Eribulin/Cyclophosphamide or Docetaxel/Cyclophosphamide as Neoadjuvant Therapy in Locally Advanced HER2-Negative Breast Cancer". The investigators propose a randomized phase II study evaluating the pCR and toxicity profiles of combination eribulin/cyclophosphamide (ErC) and docetaxel /cyclophosphamide (TC) as neoadjuvant therapy for locally advanced HER2-negative breast cancer.
What is the current status of trial NCT01527487?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 76 participants. The study started on 2012-06. Estimated completion is 2016-07.
What interventions are being tested in trial NCT01527487?
The interventions under investigation include: Cyclophosphamide (DRUG), Docetaxel (DRUG), Eribulin (DRUG).
Who is sponsoring clinical trial NCT01527487?
This trial is sponsored by SCRI Development Innovations, which has 146 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.